Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

This study has been completed.
Sponsor:
Collaborator:
Sirna Therapeutics Inc.
Information provided by:
Allergan
ClinicalTrials.gov Identifier:
NCT00363714
First received: August 10, 2006
Last updated: August 14, 2008
Last verified: August 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2007
  Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
No publications provided by Allergan

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):